Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Nivolumab safe and effective for cancer patients with HIV

Gobert et al. ESMO 2018, Abstract 1213P_PR.

Key clinical point: Patients with HIV who are treated with nivolumab, a programmed death-1 (PD-1) inhibitor, appear to have similar safety and efficacy outcomes compared with HIV-negative patients treated with the same agent.

Major finding: No immune-related adverse events or deaths due to drug toxicity occurred.

Study details: A retrospective analysis of 20 patients with HIV who received nivolumab immunotherapy.

Disclosures: Jean-Philippe Spano, principal investigator, disclosed relationships with Gilead, Roche, BMS, and others.

Read the article.


Gobert et al. ESMO 2018, Abstract 1213P_PR.